A preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Objective: Oxidative imbalance has emerged as a treatment target in bipolar disorder. As very limited data are available on the clinical use of antioxidants for mania, we report here results from a post hoc and exploratory subgroup analysis of a randomized, placebo-controlled trial of N-acetyl cysteine (NAC). Methods: This was a placebo-controlled, randomized, clinical trial assessing the effect of NAC over 24 weeks in mania or hypomania. Symptomatic and functional outcomes were collected over the study period. Results: Fifteen participants were available for this report; two participants in each group failed to complete all assessments. Within-group analyses pointed to an improvement in the NAC group on manic symptoms and worsening in the placebo group on depressive symptoms at endpoint. Conclusions: Although the sample size was small, these results indicated within-group efficacy for this glutathione precursor as compared to placebo. Future trials specifically designed to demonstrate the efficacy of NAC in mania are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are four placebo‐controlled trials that investigated divalproex (level 4),432 N‐acetylcysteine (level 4),433 and quetiapine (level 4)434, 435; and one open‐label study of risperidone (level 4)436 in acute hypomania.”
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 3×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
MethodJournal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
Method(1993) · PubMed · Cited by 1,900
Keller, M. B. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800180050009 · Cited by 1,643 · cited 4×
“…Evaluation for the Longitudinal Interval Follow-up Evaluation (SLICE-LIFE), the Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool (LIFE-RIFT; Keller et al., 1987) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q; Endicott et al., 1993).”
MethodInfluentialBerk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationMorosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101004323.x · Cited by 1,097 · cited 4×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
MethodInfluentialOxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · cited 2×
“Clinical and animal studies demonstrate that mood stabilizers improve oxidative stress parameters (Ng et al., 2008; Frey et al., 2006; Machado-Vieira et al., 2010).”
BackgroundSelf-citationJones, S. H., Thornicroft, G., Coffey, M., & Dunn, G. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.5.654 · Cited by 1,015 · cited 4×
“NAC: N-acetyl cysteine; YMRS: Young Mania Rating Scale; MADRS: Montgomery–Asberg Depression Rating Scale; GAF: Global Assessment of Functioning; BDRS: Bipolar Depression Rating Scale; LIFE-RIFT: Longitudinal Interval Follow-up Evaluation – Range of Impairment Functioning Tool; SLICE-LIFE: Streamlined Longitudinal Inte…”
MethodInfluential
Research works printed but not linked: 1
- Endicott J, 1993, Psychopharmacology Bulletin, 29, 321
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Self-citationRaghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
“Data from various subgroup analyses further support the benefits of NAC in terms of symptom severity, functioning, response rate, symptom remission, and quality of life [155-158].”
Self-citationRosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
“This analysis revealed a greater improvement in symptoms of mania in the NAC group compared to placebo [118].”
ResultBiological hypotheses and biomarkers of bipolar disorder
Sigitova, E., Fišar, Z., Hroudová, J., Cikánková, T., & Raboch, J. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12476 · Cited by 235
“Antioxidants, such as N-acetylcysteine (NAC) seem to be beneficial in treatment of both major depressive episodes(236) and manic/hypomanic episodes.(237) NAC is a promising novel therapeutic option for BD and other neuropsychiatric disorders, because NAC targets glutamatergic transmission, glutathione, neurotrophins,…”
Background
Metadata
- Authors
- Vieira da Silva Magalhães, P., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M.
- Affiliations
- National Institute for Translational Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Deakin University (AU)
- Monash University (AU)
- The University of Sydney (AU)
- School of Medicine, Deakin University, Geelong, Australia
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2013-03-14
- Volume
- 47
- Issue
- 6
- Pages
- 564-568
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2161212886
- Cited by
- 58
- References
- 43
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 8 · 2017: 4 · 2016: 10 · 2015: 7 · 2014: 3 · 2013: 3
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- N-acetylcysteine, mania, hypomania, bipolar disorder, oxidative imbalance, antioxidants, glutathione precursor, manic symptoms, depressive symptoms, subgroup analysis
- MeSH terms
- Acetylcysteine, Adult, Antioxidants, Bipolar Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania. https://app.cochat.ai/papers/10.1177/0004867413481631
- The paper
- Vieira da Silva Magalhães, P., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2013). A preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867413481631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.